DCGI orders suspension of Serum’s India trials of AstraZeneca’s COVID-19 vaccine

By: |
September 12, 2020 10:56 AM

V.G. Somani, the drugs controller general of India, has also asked for increased safety monitoring of those already vaccinated with the experimental vaccine, ANI reported citing an order issued by the regulator.

AstraZeneca, AstraZeneca covid 19 vaccine, Serum Institute of India, covid 19 vaccine, COVID-19 vaccine candidate, coronavirus pandemic, latest news on covid 19 vaccineThe drugs regulator had given last month Serum approval to run mid- to late-stage clinical trials on the leading COVID-19 vaccine candidate to determine its safety and ability to trigger immune response. (Representational image: Reuters photo)

India’s drug regulator has asked Serum Institute of India to suspend recruitment in its clinical trials of AstraZeneca Plc’s potential COVID-19 vaccine in the country until further orders, Reuters partner ANI reported on Friday.

V.G. Somani, the drugs controller general of India, has also asked for increased safety monitoring of those already vaccinated with the experimental vaccine, ANI reported citing an order issued by the regulator. The move places further restrictions on the trials, which have already been put on hold by Serum on Thursday after the DCGI had asked the vaccine maker for details on the suspension of trials overseas, in a show-cause notice that was reviewed by Reuters.

Friday’s order has been issued after Serum responded to the show-cause notice, according to ANI. Somani had warned that Serum could face action if it did not offer an explanation for why the trials should not be suspended until patient safety is established, after AstraZeneca decided earlier in the week to pause global trials in the wake of an unexplained illness in a study participant.

The DCGI, Serum and AstraZeneca did not immediately respond to Reuters’ requests for comment.The drugs regulator had given last month Serum approval to run mid- to late-stage clinical trials on the leading COVID-19 vaccine candidate to determine its safety and ability to trigger immune response.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Delhi records over 40 COVID-19 deaths for second straight day; cases rise to 2,71,114
2COVID-19: Kerala witnesses highest single-day spurt of 7,445 new cases; total cases rise to 1.74 lakh
3ICMR’s 2nd sero-survey shows Indians far from achieving herd immunity against COVID-19: Harsh Vardhan